Beta Bionics (BBNX) Q2 FY26 earnings call

Beta Bionics demonstrated strong commercial momentum in Q2 FY26, driven by robust Islet sales and a successful pharmacy channel strategy. The company is making significant progress across its innovation pipeline, including the MINT patch pump, bi-hormonal system, and indication expansion for Islet, positioning it for future growth. Despite increased operating expenses to support commercial and R&D initiatives, management reiterated full-year revenue guidance and raised its gross margin outlook, reflecting confidence in its underlying profitability and market strategy.